Publikationen in Zusammenarbeit mit Forschern von Tianjin Medical University Cancer Institute and Hospital (1)

2023

  1. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

    Journal of Clinical Oncology